Table 1 Atogepant clinical trials conducted in participants with episodic migraine
Study (ClinicalTrials.gov Identifier) | Phase | No. Treated | Study Design | Study Drug/Dose | Dosing Frequency | Study Visits |
|---|---|---|---|---|---|---|
MD-01 (NCT02848326) | 2b/3 | 825 | Randomized, double-blind, placebo-controlled | Atogepant 10, 30, or 60 mg or placebo | All doses, once daily; 30 and 60 mg, twice daily | Weeks 2, 4, 6, 8, 12; follow-up week 16 |
ADVANCE (NCT03777059) | 3 | 902 | Randomized, double-blind, placebo-controlled | Atogepant 10, 30, or 60 mg or placebo | Once daily | Weeks 2, 4, 6, 8, 12; follow-up week 16 |
Study 302 (NCT03700320) | 3 | 739 | Randomized, open label | Atogepant 60 mg or standard care | Once daily | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52; follow-up week 56 |
Study 309 (NCT03939312) | 3 | 655 | Open label | Atogepant 60 mg | Once daily | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40; follow-up week 44 |